# Alnylam Pharmaceuticals

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/alnylam-pharmaceuticals/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | biopharmaceutical company |
| OpenAlex ID | https://openalex.org/F4320309056 |
| ROR ID | https://ror.org/00thr3w71 |
| Works | 2,232 |

## Funder papers

- [Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/executive-summary-of-the-kdigo-2021-guideline-for-the-management-of-glomerular/)
- [Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/efficacy-of-dapagliflozin-on-renal-function-and-outcomes-in-patients-with-heart/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)
- [The pathogenesis of IgA nephropathy and implications for treatment](https://scholariq.org/papers/the-pathogenesis-of-iga-nephropathy-and-implications-for-treatment/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial](https://scholariq.org/papers/effect-of-empagliflozin-on-heart-failure-outcomes-after-acute-myocardial/)
- [Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD](https://scholariq.org/papers/correlates-and-consequences-of-an-acute-change-in-egfr-in-response-to-the-sglt2/)
- [Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes](https://scholariq.org/papers/oral-semaglutide-and-heart-failure-outcomes-in-persons-with-type-2-diabetes/)
- [Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey](https://scholariq.org/papers/real-world-experience-of-teduglutide-use-in-adults-with-short-bowel-syndrome-a/)
- [Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial](https://scholariq.org/papers/simultaneous-initiation-of-finerenone-and-empagliflozin-across-the-spectrum-of/)
- [A comparison of quality-adjusted life years in older adults after heart transplantation versus long-term mechanical support: Findings from the SUSTAIN-IT study](https://scholariq.org/papers/a-comparison-of-quality-adjusted-life-years-in-older-adults-after-heart/)
- [Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF](https://scholariq.org/papers/sacubitril-valsartan-and-quality-of-life-assessed-using-the-euroqol-five/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.